Bile Acid Binding Resins Improve Glucagon Receptor Agonist‐Mediated Weight Loss in Diet‐Induced Obese Mice
Obesity · 2026
DOI: 10.1002/oby.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Teayoun Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Bi…. Hauptthemen laut MEDLINE: Obesity, Bile Acids and Salts, Weight Loss, Cholestyramine Resin. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, American Heart Association.
Abstract (Originalsprache)
Objective
Glucagon‐receptor (GCGR) agonism reguglates bile acid (BA) metabolism and promotes weight loss in diet‐induced obese (DIO) mice. Thus, we hypothesized that BA signaling contributes to GCGR‐stimulated weight loss.
Methods
To test this hypothesis, we utilized BA‐binding resins (BARs; colesevelam [Colsv] and cholestyramine [Cstyr]) to prevent intestinal BA reuptake. DIO C57Bl/6J mice were administered the GCGR agonist IUB288 or vehicle, in the presence or absence of BARs.
Results
To our surprise, combined IUB288 and Colsv treatment reduced body weight and food intake compared to IUB288 or Colsv treatment groups in high fat diet (HFD)‐fed mice. Moreover, acute IUB288 + Colsv treatment reduced fasting‐stimulated HFD, but not chow, intake compared to IUB288 or Colsv treatments alone. We observed improved glucose homeostasis and reduced plasma cholesterol with combined IUB288 and Colsv, but not Colsv alone. Excitingly, liver steatosis was suppressed with IUB288 but not Colsv alone, and this benefit was further enhanced with combined treatment. Plasma BA profiles were regulated by both IUB288 and Colsv with concomitant modulation of liver and ileum BA regulatory mRNA expression. Similar findings were observed with the first‐generation BAR Cstyr.
Conclusions
Together, these studies suggest that BARs enhance the antiobesity effect of GCGR agonism in DIO mice, representing a novel antiobesity strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
- Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
ORCID-Profile: Jessica Antipenko, Kirk Habegger
Förderung
- NIDDK NIH HHS
- NIH HHS
- American Heart Association
- Lilly Research Award Program
- National Institute of Diabetes and Digestive and Kidney Diseases
- Eli Lilly and Company
Zitieren
APA
Kim, T., Pearson, M. J., Hong, H., Nason, S., Seck, K., Antipenko, J., Presedo, N., DiMarchi, R., Roell, W. C., & Habegger, K. (2026). Bile Acid Binding Resins Improve Glucagon Receptor Agonist‐Mediated Weight Loss in Diet‐Induced Obese Mice. Obesity. https://doi.org/10.1002/oby.70087
Vancouver
Kim T, Pearson MJ, Hong H, Nason S, Seck K, Antipenko J, et al. Bile Acid Binding Resins Improve Glucagon Receptor Agonist‐Mediated Weight Loss in Diet‐Induced Obese Mice. Obesity. 2026. doi:10.1002/oby.70087
BibTeX
@article{Kim2026,
author = {Kim, Teayoun and Pearson, Mackenzie J and Hong, Huixian and Nason, Shelly and Seck, Khadija and Antipenko, Jessica and Presedo, Natalie and DiMarchi, Richard and Roell, William C and Habegger, Kirk},
title = {Bile Acid Binding Resins Improve Glucagon Receptor Agonist‐Mediated Weight Loss in Diet‐Induced Obese Mice},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70087}
}
EUVIMED